Navigation Links
Oral contraceptives associated with increased risk of lupus
Date:4/7/2009

The ratio of women to men with the autoimmune disease systemic lupus erythematosus (SLE) is nine to one and the incidence increases after puberty. Hormones secreted by the body are therefore believed to play an important role in the origins of the disease. A new large, population-based observational study found that the use of oral contraceptives was associated with an increased risk of SLE, particularly among women who had recently started taking them. The study was published in the April issue of Arthritis Care & Research (http://www3.interscience.wiley.com/journal/77005015/home).

Led by Dr. Samy Suissa of the Centre for Clinical Epidemiology at Jewish General Hospital of McGill University in Montreal, researchers obtained data on more than 1.7 million women ages 18-45 from the U.K. General Practice Research Database, which contains more than 6 million people. The women all had prescriptions for combined oral contraceptives (COCs) containing estrogen and progestogen. During an average of eight years of follow-up, 786 women had a first-time diagnosis of SLE. Each case was matched with up to 10 controls among women without SLE at the time of the case's diagnosis.

The results showed that the use of COCs was associated with a significant increased risk of newly diagnosed SLE. This was mostly limited to the first three months of use with first- and second-generation contraceptives containing higher doses of estrogen, suggesting "an acute effect in susceptible women and possibly a dose-response effect of estrogen on SLE onset," according to the authors. They note that estrogen can directly modulate the immune response, which could complete the action of some sex-linked genes and contribute to the genetic predisposition of the disease, and it has also been shown to have an effect on the breakdown of immune tolerance seen in SLE.

Previous studies on the risk of SLE following use of oral contraceptives have had conflicting results, but the results of the current study are consistent and complement those of the NIH-sponsored Nurses' Health Study. "Our findings that longer-term use of contraceptives is associated with an increased risk of incident SLE (albeit of lower magnitude) and that current use of contraceptives with higher doses of ethinyl estradiol is associated with an increased risk of incident SLE, suggest a possible dose-response effect of estrogen on SLE onset, which could be an alternative or additional mechanism to favor occurrence of the disease," the authors state. They note that the absence of significant increased risk in third-generation contraceptives may be related to the lower doses of estrogen compared to earlier generations.


'/>"/>

Contact: Sean Wagner
medicalnews@bos.blackwellpublishing.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Oral Contraceptives Cut Ovarian Cancer Risk
2. Barr and Bayer Sign Supply and Licensing Agreements for Launch of Generic Yasmin(R) and Yaz(R) Oral Contraceptives
3. UNC trial: oral contraceptives may ease suffering of women with severe PMS
4. Newer Contraceptives Dont Increase Heart Risk
5. New study shows promise in reducing surgical risks associated with surgical bleeding
6. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
7. Study, meta-analysis examine factors associated with death from heatstroke
8. Increased distance to physician associated with thicker skin cancer at diagnosis
9. Minorities more likely to have sleep durations associated with increased mortality
10. Income inequality associated with overnourishment and undernourishment in India
11. Maternal depression and controlling behavior associated with increased stress response in infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, ... ... Standards Consortium (CDISC) announces today the open availability of a new CDISC ... and catalogs for registering clinical trials. This innovative standard will make it ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of ... determinant of childhood mortality. This is particularly true in underdeveloped parts of Africa where ... University of New England’s campus in Tangier, Morocco, will examine this global health issue ...
(Date:4/28/2016)... ... April 28, 2016 , ... One way to ignore solid evidence is to ... But we toss the baby out with the bathwater when we ignore all studies ... higher-quality studies and otherwise making better use of education policy research. , “When readers ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... of miniature microphones and headsets announced today that the US Patent Office has ... in-earphones into a structure. This innovative design creates a lightweight and modular audio ...
(Date:4/28/2016)... ... April 28, 2016 , ... SyncDog, Inc. , ... leading secure mobility workstation suite, SentinelSecure™, at MobileIron’s 6th annual Mobile First Conference ... will be MobileIron’s 6th Mobile First Conference and will feature immersive training, collaboration, ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  The blood testing market in ... to Kalorama Information and The Freedonia Group in a ... acid testing.  The healthcare research firm said that ... blood collection stations and in improving testing at the ... report, Blood Testing Market in China ...
(Date:4/28/2016)... --  Acsis , a leading provider of supply chain ... and advisory firm IDC has named it a " ... Track and Trace Software 2016 Vendor Assessment (doc # ... the capabilities and business strategies of 10 vendors in ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
Breaking Medicine Technology: